HIV / AIDS in the News

HIV-1 adapts to lost IP6 coordination through second-site mutations that restore conical capsid assembly - Nature.com

 

Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial - Yahoo Finance

 

JD Vance now says Haitian immigrants are spreading HIV after bizarre pet-eating claim flops - Yahoo! Voices

 

Gilead’s twice-yearly lenacapavir for HIV PrEP bests Truvada - The Pharma Letter

 

KFF Dashboard: Progress Toward Global HIV Targets in PEPFAR Countries - KFF

 

USCHA 2024 - Federal Update on HIV Programs & Syndemic Approach - HIV.gov

 

In a historic move, Colombia bypasses a patent to access a key HIV drug - Al Jazeera English

 

AIDS/LifeCycle to End in 2025 After 30 Years of Fundraising for HIV Services - The Pride LA

 

Holly Johnson recalls being "canceled" after revealing HIV status: "It was a bit like living in a desert" - Queerty

 

IVF in Ireland: HIV-positive woman calls for change - BBC.com

 

HIV services discontinued at Minneapolis housing complex - KSTP

 

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug - The Wall Street Journal

 

Biden-Harris Administration Issues Proposed Rule to Expand Access to Life-Saving Organs for People with HIV - HIV.gov

 

Failing to Meet Global Targets Means 17.7 Million More AIDS-Related Deaths - Pharmacy Practice News

 

Gilead Pops After New Shot Blocks 99.9% Of HIV Infections - Investor's Business Daily

 

Nebraska campaign targets HIV awareness with testing and education - KNOP

 

Nebraska campaign targets HIV awareness with testing and education - KNOP

 

Weld County receives grant for an HIV prevention program - Greeley Tribune

 

Fenway Health Commends PUSPOSE 2 Twice Yearly HIV Pre-Exposure Prophylaxis (PrEP) Injection Study Results - PR Web

 

Gilead’s twice-yearly lenacapavir outperforms Truvada in men - Clinical Trials Arena

 

Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access? - U.S. News & World Report

 

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections - Benzinga

 

Francisco Ruiz is bringing his truth to national HIV/AIDS policy - HSPH News

 

Gilead’s (NASDAQ:GILD) Latest Study Shows Further Progress Against HIV - TipRanks

 

Twice-yearly injection reduced HIV infections by 96 percent, company says - The Hill

 

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug - The Wall Street Journal

 

Triple antibody therapy shows promise for long-lasting HIV control - Medical Xpress

 

National HIV/AIDS Strategy Quality of Life Goals Unlikely to Be Met - AJMC.com Managed Markets Network

 

Creator and host Karl Schmid fights HIV stigma with knowledge - Plus

 

PUBLIC HEALTH CORNER: National HIV/AIDs & Aging Awareness Day - Kirksville Daily Express and Daily News